Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity

SummaryConventionally in vitro cytotoxicity assays are performed as single-end-point determinations. To compensate for the diversity of growth rates among different cell lines in this report we describe a computerized kinetic chemosensitivity assay based on quantification of biomass by staining cells with crystal violet. As a prerequisite four human breast cancer cell line (MDA-MB-231, MCF-7, T-47-D and ZR-75-1) were characterized with regard to oestrogen and progesterone receptor content, modal chromosome number and proliferation kinetics depending on the number of passages in culture. With prolonged time in culture for ZR-75-1 exposed to various concentrations of cisplatinum a dose-related increase in drug effect was observed. Owing to a correction of the T/C values for the initial cell mass (at the time when drug is added) a sharp distinction between cytostatic and cytocidal drug effects becomes obvious in plots of corrected T/C values versus time of incubation. The influence of the untreated control on the corrected T/C values and possible time courses of theoretical inhibition profiles (reflecting cytostatic, transient cytotoxic or cytocidal drug effects as well as development of resistance) and their relationship to the corresponding growth curves of drugtreated cells are discussed. Chemosensitivity assays with diethylstilbestrol dipropionate, tamoxifen, melphalan, cisplatinum, vinblastine, Adriamycin and 5-fluorouracil prove the theoretical considerations to be true for MDA-MB-231, MCF-7, T-47-D and ZR-75-1 human breast cancer cell lines in practice.

[1]  P. Skehan,et al.  Non‐Exponential Growth By Mammalian Cells In Culture , 1984, Cell and tissue kinetics.

[2]  J. Whang‐Peng,et al.  Cytogenetic studies of human breast cancer lines: MCF-7 and derived variant sublines. , 1983, Journal of the National Cancer Institute.

[3]  J. Yunis The chromosomal basis of human neoplasia. , 1983, Science.

[4]  S. O’Brien,et al.  Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. , 1978, Cancer research.

[5]  H. Reile,et al.  Computerized determination of growth kinetic curves and doubling times from cells in microculture. , 1990, Analytical biochemistry.

[6]  M. Radu,et al.  Establishment and characterization of a cell line of human breast carcinoma origin. , 1979, European journal of cancer.

[7]  J. Venditti Preclinical drug development: rationale and methods. , 1981, Seminars in oncology.

[8]  A. Eastman,et al.  [dl-1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[9]  J. Shine,et al.  Genetic instability and the development of steroid hormone insensitivity in cultured T 47D human breast cancer cells. , 1988, Cancer research.

[10]  M. Namer,et al.  HPLC micromethod for simultaneous measurement of estradiol, progesterone, androgen and glucocorticoid receptor levels. Application to breast cancer biopsies. , 1987, European journal of cancer & clinical oncology.

[11]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[12]  L V Rubinstein,et al.  Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. , 1990, Journal of the National Cancer Institute.

[13]  W. Kueng,et al.  Quantification of cells cultured on 96-well plates. , 1989, Analytical biochemistry.

[14]  M. Olivé,et al.  Breast tumor cell lines from pleural effusions. , 1974, Journal of the National Cancer Institute.

[15]  R. Gillies,et al.  Determination of cell number in monolayer cultures. , 1986, Analytical biochemistry.

[16]  James B. Mitchell,et al.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. , 1987, Cancer research.

[17]  R. Freshney Animal cell culture : a practical approach , 1992 .

[18]  O. N. Meland,et al.  Carcinoma of the breast. , 1948, Annals of western medicine and surgery.

[19]  J. H. Peters,et al.  Monoklonale Antikörper : Herstellung und Charakterisierung , 1990 .

[20]  B. Baguley,et al.  The use of human cancer cell lines as a primary screening system for antineoplastic compounds. , 1984, European journal of cancer & clinical oncology.

[21]  P Skehan On the normality of growth dynamics of neoplasms in vivo: a data base analysis. , 1986, Growth.

[22]  R. Makuch,et al.  Application of a human tumor colony-forming assay to new drug screening. , 1985, Cancer research.

[23]  P. Skehan,et al.  Postconfluency MDCK monolayers as an in vitro model of solid tumor chemosensitivity , 1986, Cell Biology and Toxicology.

[24]  A. Long,et al.  A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.

[25]  B. Drewinko,et al.  Comparison of in vitro methods to determine drug-induced cell lethality. , 1976, Cancer research.

[26]  D. Scudiero,et al.  Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. , 1988, Cancer research.

[27]  A. P. Wilson Cytotoxicity and viability assays , 1986 .

[28]  D A Scudiero,et al.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. , 1988, Cancer research.

[29]  B. Czepulkowski,et al.  Human cytogenetics : a practical approach , 1986 .

[30]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[31]  N. Knebel,et al.  Platinum complexes with a selective action on estrogen receptor-positive mammary tumors. , 1989, Anti-cancer drug design.

[32]  D A Scudiero,et al.  Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. , 1989, Journal of the National Cancer Institute.

[33]  R J Hay,et al.  The seed stock concept and quality control for cell lines. , 1988, Analytical biochemistry.

[34]  R. Sutherland,et al.  Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro. , 1987, Cancer research.

[35]  Venditti Jm The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary. , 1983 .

[36]  R. Freshney,et al.  Assay of anti-cancer drugs in tissue culture: conditions affecting their ability to incorporate 3H-leucine after drug treatment. , 1975, British Journal of Cancer.